gdc
Lung Cancer

Drugs for Lung Cancer

Here are the financial support services available to patients receiving treatment for Lung Cancer.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Celgene
800-931-8691

Abraxane is a microtubule inhibitor used, in combination with carboplatin, for the treatment of patients with locally advanced or metastatic non–small-cell lung cancer.

Celgene offers 3 financial assistance programs for patients using Abraxane injectable suspension:

Celgene Commercial Co-pay Program

This program reduces the copay for Abraxane to $25 or less, for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Abraxane for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Alecensa (alectinib)

Drug company: Genentech
866-422-2377

Alecensa is a kinase inhibitor used for the treatment of all patients with ALK-positive metastatic non–small-cell lung cancer, as detected by a specific test.

Genentech offers 2 financial assistance programs for patients using Alecensa:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Alecensa free of charge to uninsured or underinsured patients whose annual household income is less than $100,000. Alecensa is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Alimta (pemetrexed)

Drug company: Eli Lilly
866-472-8663

Alimta is a folate analog metabolic inhibitor used for the treatment of patients with locally advanced or metastatic nonsquamous non–small-cell lung cancer, as an initial treatment, in combination with cisplatin, or as a maintenance treatment.

Lilly PatientOne offers 2 financial assistance programs for patients using Alimta:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Alimta.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover therapy) and an annual household income up to 500% of the federal poverty level, this program provides Alimta at no cost.

Alunbrig (brigatinib)

Drug company: Takeda Oncology
844-217-6468

Alunbrig is a kinase inhibitor used for the treatment of patients with ALK-positive metastatic non–small-cell lung cancer progressing during, or in a patient who is intolerant of, crizotinib therapy.

Takeda Oncology’s Alunbrig 1Point offers 2 financial assistance programs for patients using Alunbrig:

Alunbrig Co-Pay Assistance Program

Through this program, eligible patients with commercial insurance will pay no more than $10 a month for Alunbrig, with maximum assistance of $25,000 a year.

Alunbrig Patient Assistance Program

This program may provide Alunbrig at no cost for up to 1 year to eligible patients who are uninsured or underinsured.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with nonsquamous non–small-cell lung cancer, in combination with carboplatin and paclitaxel.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Card

For privately insured patients, this program ensures a $25 copay, with up to $25,000 provided annually, and it has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $100,000. Avastin is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of the income (regardless of insurance).

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used, in combination with docetaxel, for the treatment of patients with metastatic non–small-cell lung cancer.

Lilly PatientOne offers 2 financial assistance programs for patients using Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 for a dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover therapy) and a household income at or below 500% of the federal poverty level, this program provides Cyramza at no cost.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used, in combination with cisplatin, for the treatment of patients with non–small-cell lung cancer.

Lilly PatientOne offers 1 financial assistance program for patients using Gemzar:

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover therapy) and a household income at or below 500% of the federal poverty level, this program provides Gemzar at no cost.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used, in combination with cisplatin, for the treatment of patients with non–small-cell lung cancer.

Lilly PatientOne offers 1 financial assistance program for patients using Gemzar:

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover therapy) and a household income at or below 500% of the federal poverty level, this program provides Gemzar at no cost.

Gilotrif (afatinib)

Drug company: Boehringer Ingelheim
877-814-3915

Gilotrif is a kinase inhibitor used as a first-line treatment for patients with metastatic non–small-cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations. Gilotrif is also used for patients with metastatic, squamous non–small-cell lung cancer.

Boehringer Ingelheim’s Solutions Plus offers 5 financial assistance programs for patients using Gilotrif.

Gilotrif Plus Co-pay Assistance Program

This program ensures that commercially insured patients pay a maximum out-of-pocket cost of $25 monthly for Gilotrif. This program has no income eligibility, benefit cap, or any additional paperwork requirements.

Gilotrif Bridge Program

The Bridge Program offers eligible commercially insured patients who are experiencing a delay of more than 5 days of insurance approval can receive a 15-day free supply of Gilotrif for an FDA-approved indication.

Gilotrif Dose Exchange Program

This program facilitates the transition to a new dose of Gilotrif at no cost to eligible commercially insured patients, and eliminates an additional copay for Gilotrif for 1 month.

Reimbursement and Access Managers

Boehringer Ingelheim also offers patients and providers access to reimbursement services through reimbursement and access specialists who provide appeals support for prior authorization denials and assistance with ordering patient support kits for dispensing pharmacies.

BI Cares Foundation Patient Assistance Program

This program offers free treatment with Gilotrif to eligible, uninsured, or underinsured Medicare patients who have been previously denied financial assistance from other foundations.

Hycamtin (topotecan) injection

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used for the treatment of patients with small-cell lung cancer and platinum-sensitive disease progressing after first-line chemotherapy.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Hycamtin for free for 1 year, or until a prescription drug coverage becomes available to them.

Iressa (gefitinib)

Drug company: AstraZeneca
844-275-2360

Iressa is a tyrosine kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer that is associated with EGFR exon 19 deletions or exon 21 substitution mutations.

AstraZeneca Acess 360 offers 2 financial assistance programs for patients using Iressa:

Access 360 IRESSA Patient Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay no more than $0 per dose of Iressa, with a maximum savings of $26,000 annually. Eligible patients must have private health insurance that partially covers the medication costs for Iressa.

AZ&Me Prescription Savings Program

This prescription savings program offers free Iressa to qualifying patients without insurance, those who have Medicare Part D coverage, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in Limited Income Subsidy for Medicare Part D, and/or a life-changing event in the past year that affected finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Iressa (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used as a single agent for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; for patients with metastatic NSCLC expressing PD-L1, as determined by an FDA-approved test and disease progression during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression with an FDA-approved therapy for these mutations before using Keytruda. Keytruda is also used, in combination with pemetrexed and carboplatin, as first-line treatment of patients with metastatic nonsquamous NSCLC.

The Merck Access Program offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have a household income of $60,300 or less for individuals, $81,200 or less for couples, or $123,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for medicines, may request that an exception be made, provided their household income is not above a set limit.

Mekinist (trametinib) and Tafinlar (dabrafenib)

Drug company: Novartis
800-245-5356

Mekinist and Tafinlar are kinase inhibitors that are used in combination for the treatment of patients with metastatic non–small-cell lung cancer with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using the combination of Mekinist and Tafinlar:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Mekinist and Tafinlar combination. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Mekinist and Tafinlar combination for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive the combination of Mekinist and Tafinlar for free for 1 year, or until a prescription drug coverage becomes available to them.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer.

Bristol-Myers Squibb (BMS) Access Support provides 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Opdivo, may be eligible for help paying for their prescription if they are being treated as an outpatient and have an annual household income of less than 300% of the federal poverty level.

Photofrin (porfimer)

Drug company: Pinnacle Biologics
855-215-2720

Photofrin is used for the treatment of patients with microinvasive endobronchial non–small-cell lung cancer. Photofrin is also used to treat patients with completely or partially obstructing endobronchial non–small-cell lung cancer.

Pinnacle Biologics offers 1 financial assistance program for patients using Photofrin:

Photofrin Patient Assistance Program

This program is designed to assist financially disadvantaged patients who have no prescription coverage. Eligible patients must have an annual household income at or below 200% of the federal poverty level.

Portrazza (necitumumab)

Drug company: Eli Lilly
866-472-8663

Portrazza is an EGFR antagonist used as first-line treatment, in combination with gemcitabine and cisplatin, for patients with metastatic squamous non–small-cell lung cancer.

Lilly PatientOne offers 2 financial assistance programs for patients using Portrazza:

Lilly PatientOne Co-pay Program

For privately insured patients whose household income does not exceed $100,000 or 500% of the federal poverty level, this program provides up to $42,000 annually so that the patient pays no more than $25 per dose for Portrazza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance, or those whose insurance does not cover therapy, and a household income at or below 500% of the federal poverty level, this program provides Portrazza at no cost.

Tagrisso (osimertinib)

Drug company: AstraZeneca
844-275-2360

Tagrisso is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer and EGFR T790M mutation.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Tagrisso:

Access 360 Tagrisso Patient Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay no more than $0 monthly for Tagrisso, with a maximum savings of $26,000 annually. Eligible patients must have a private health insurance that partially covers medication costs for Tagrisso.

AZ&Me Prescription Savings Program

This prescription savings program offers free Tagrisso to qualifying patients without insurance, those who have Medicare Part D coverage, and those who receive Tagrisso through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in Medicare’s Limited Income Subsidy, and/or a life-changing event in the past year that affected their finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll), and a supply of Tagrisso (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Tarceva (erlotinib)

Drug company: Genentech
866-422-2377

Tarceva is a kinase inhibitor used for the treatment of patients with locally advanced or metastatic non–small-cell lung cancer, and as a first-line treatment for patients with metastatic non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 substitution mutations.

Genentech offers 2 financial assistance programs for patients using Tarceva:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for Tarceva, with up to $24,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Tarceva free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Tarceva is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer.

Genentech offers 2 financial assistance programs for patients using Tecentriq:

Genentech BioOncology Co-pay Card

For patients with insurance, the program ensures a $25 copay, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Tecentriq free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Tecentriq is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of the income (regardless of insurance).

Xalkori (crizotinib)

Drug company: Pfizer
877-744-5675

Xalkori is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer with ALK or ROS1 mutation.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Xalkori:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients who have private insurance so that their copay for Xalkori is $0 monthly, with a maximum savings of $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are uninsured and patients with government insurance. Uninsured patients may qualify to receive Xalkori for free, or at a savings. Eligible patients with government insurance who cannot find independent charitable foundation support, may receive Xalkori for free.

Zykadia (ceritinib)

Drug company: Novartis
800-245-5356

Zykadia is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer and ALK mutation, as detected by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Zykadia:

Novartis Oncology Universal Co-Pay Card

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Zykadia for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Zykadia for free for 1 year, or until a prescription drug coverage becomes available to them.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Zykadia for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Zykadia for free for 1 year, or until a prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Lung Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Hycamtin (topotecan) injection
  • Drug company
  • Novartis
  • Indication
  • Small-cell lung cancer with platinum-sensitive disease progressing after first-line chemotherapy
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Metastatic NSCLC with high PD-L1 and no EGFR or ALK mutations, first line

    Metastatic NSCLC expressing PD-L1 and disease progression during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression during an FDA-approved therapy for these mutations before using Keytruda

    Metastatic nonsquamous NSCLC, as first-line, in combination with pemetrexed and carboplatin
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932
NSCLC = non–small-cell lung cancer.
Last modified: March 7, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country